nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—melanoma	0.139	1	CbGaD
Buprenorphine—ABCG2—Vemurafenib—melanoma	0.108	0.187	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—melanoma	0.0716	0.124	CbGbCtD
Buprenorphine—CYP1A2—Carmustine—melanoma	0.0562	0.0976	CbGbCtD
Buprenorphine—CYP1A2—Vemurafenib—melanoma	0.0444	0.0772	CbGbCtD
Buprenorphine—CYP3A4—Temozolomide—melanoma	0.0425	0.0738	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—melanoma	0.0369	0.0642	CbGbCtD
Buprenorphine—CYP2D6—Vemurafenib—melanoma	0.0366	0.0636	CbGbCtD
Buprenorphine—CYP1A2—Dacarbazine—melanoma	0.034	0.0592	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0273	0.0474	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—melanoma	0.0273	0.0474	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—melanoma	0.0258	0.0449	CbGbCtD
Buprenorphine—CYP3A4—Vemurafenib—melanoma	0.0233	0.0404	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—melanoma	0.0205	0.0356	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—melanoma	0.0133	0.0232	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—melanoma	0.00798	0.0139	CbGbCtD
Buprenorphine—Naloxone—TLR4—melanoma	0.00239	0.711	CrCbGaD
Buprenorphine—Naltrexone—ABCB1—melanoma	0.000391	0.116	CrCbGaD
Buprenorphine—Lethargy—Docetaxel—melanoma	0.000369	0.00246	CcSEcCtD
Buprenorphine—Urethral disorder—Temozolomide—melanoma	0.000369	0.00245	CcSEcCtD
Buprenorphine—Eye disorder—Carmustine—melanoma	0.000364	0.00242	CcSEcCtD
Buprenorphine—Visual impairment—Temozolomide—melanoma	0.000363	0.00241	CcSEcCtD
Buprenorphine—Erythema—Dactinomycin—melanoma	0.000362	0.00241	CcSEcCtD
Buprenorphine—Pain in extremity—Docetaxel—melanoma	0.000362	0.00241	CcSEcCtD
Buprenorphine—Flushing—Carmustine—melanoma	0.000361	0.0024	CcSEcCtD
Buprenorphine—Ill-defined disorder—Bleomycin—melanoma	0.00036	0.0024	CcSEcCtD
Buprenorphine—Diarrhoea—Vemurafenib—melanoma	0.000358	0.00238	CcSEcCtD
Buprenorphine—Migraine—Docetaxel—melanoma	0.000356	0.00237	CcSEcCtD
Buprenorphine—Eye disorder—Temozolomide—melanoma	0.000352	0.00234	CcSEcCtD
Buprenorphine—Tinnitus—Temozolomide—melanoma	0.000351	0.00233	CcSEcCtD
Buprenorphine—Malaise—Bleomycin—melanoma	0.00035	0.00233	CcSEcCtD
Buprenorphine—Flushing—Temozolomide—melanoma	0.000349	0.00232	CcSEcCtD
Buprenorphine—Cardiac disorder—Temozolomide—melanoma	0.000349	0.00232	CcSEcCtD
Buprenorphine—Dizziness—Vemurafenib—melanoma	0.000346	0.0023	CcSEcCtD
Buprenorphine—Angiopathy—Temozolomide—melanoma	0.000341	0.00227	CcSEcCtD
Buprenorphine—Mental disorder—Carmustine—melanoma	0.000341	0.00227	CcSEcCtD
Buprenorphine—Immune system disorder—Temozolomide—melanoma	0.00034	0.00226	CcSEcCtD
Buprenorphine—Mediastinal disorder—Temozolomide—melanoma	0.000339	0.00226	CcSEcCtD
Buprenorphine—Malnutrition—Carmustine—melanoma	0.000339	0.00225	CcSEcCtD
Buprenorphine—Erythema—Carmustine—melanoma	0.000339	0.00225	CcSEcCtD
Buprenorphine—Cough—Bleomycin—melanoma	0.000339	0.00225	CcSEcCtD
Buprenorphine—Chills—Temozolomide—melanoma	0.000338	0.00225	CcSEcCtD
Buprenorphine—Dehydration—Docetaxel—melanoma	0.000336	0.00224	CcSEcCtD
Buprenorphine—Ill-defined disorder—Dactinomycin—melanoma	0.000336	0.00224	CcSEcCtD
Buprenorphine—Vomiting—Vemurafenib—melanoma	0.000333	0.00221	CcSEcCtD
Buprenorphine—Dry skin—Docetaxel—melanoma	0.000331	0.00221	CcSEcCtD
Buprenorphine—Chest pain—Bleomycin—melanoma	0.000331	0.0022	CcSEcCtD
Buprenorphine—Myalgia—Bleomycin—melanoma	0.000331	0.0022	CcSEcCtD
Buprenorphine—Abdominal pain upper—Docetaxel—melanoma	0.00033	0.0022	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Docetaxel—melanoma	0.00033	0.0022	CcSEcCtD
Buprenorphine—Rash—Vemurafenib—melanoma	0.00033	0.00219	CcSEcCtD
Buprenorphine—Mental disorder—Temozolomide—melanoma	0.00033	0.00219	CcSEcCtD
Buprenorphine—Dermatitis—Vemurafenib—melanoma	0.000329	0.00219	CcSEcCtD
Buprenorphine—Back pain—Carmustine—melanoma	0.000328	0.00218	CcSEcCtD
Buprenorphine—Headache—Vemurafenib—melanoma	0.000328	0.00218	CcSEcCtD
Buprenorphine—Erythema—Temozolomide—melanoma	0.000327	0.00218	CcSEcCtD
Buprenorphine—Malnutrition—Temozolomide—melanoma	0.000327	0.00218	CcSEcCtD
Buprenorphine—Breast disorder—Docetaxel—melanoma	0.000327	0.00217	CcSEcCtD
Buprenorphine—Discomfort—Bleomycin—melanoma	0.000327	0.00217	CcSEcCtD
Buprenorphine—Malaise—Dactinomycin—melanoma	0.000327	0.00217	CcSEcCtD
Buprenorphine—Cramp muscle—Docetaxel—melanoma	0.000326	0.00217	CcSEcCtD
Buprenorphine—Nasopharyngitis—Docetaxel—melanoma	0.000323	0.00215	CcSEcCtD
Buprenorphine—Dysgeusia—Temozolomide—melanoma	0.000321	0.00213	CcSEcCtD
Buprenorphine—Confusional state—Bleomycin—melanoma	0.000319	0.00213	CcSEcCtD
Buprenorphine—Vision blurred—Carmustine—melanoma	0.000319	0.00213	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000319	0.00212	CcSEcCtD
Buprenorphine—Tremor—Carmustine—melanoma	0.000318	0.00211	CcSEcCtD
Buprenorphine—Oedema—Bleomycin—melanoma	0.000317	0.00211	CcSEcCtD
Buprenorphine—Anaphylactic shock—Bleomycin—melanoma	0.000317	0.00211	CcSEcCtD
Buprenorphine—Back pain—Temozolomide—melanoma	0.000317	0.00211	CcSEcCtD
Buprenorphine—Infection—Bleomycin—melanoma	0.000315	0.00209	CcSEcCtD
Buprenorphine—Dysphagia—Docetaxel—melanoma	0.000313	0.00208	CcSEcCtD
Buprenorphine—Agitation—Carmustine—melanoma	0.000311	0.00207	CcSEcCtD
Buprenorphine—Nausea—Vemurafenib—melanoma	0.000311	0.00207	CcSEcCtD
Buprenorphine—Vision blurred—Temozolomide—melanoma	0.000309	0.00205	CcSEcCtD
Buprenorphine—Myalgia—Dactinomycin—melanoma	0.000308	0.00205	CcSEcCtD
Buprenorphine—Bronchospasm—Docetaxel—melanoma	0.000307	0.00205	CcSEcCtD
Buprenorphine—Tremor—Temozolomide—melanoma	0.000307	0.00204	CcSEcCtD
Buprenorphine—Discomfort—Dactinomycin—melanoma	0.000305	0.00203	CcSEcCtD
Buprenorphine—Angina pectoris—Docetaxel—melanoma	0.000304	0.00203	CcSEcCtD
Buprenorphine—Ill-defined disorder—Temozolomide—melanoma	0.000304	0.00202	CcSEcCtD
Buprenorphine—Anorexia—Bleomycin—melanoma	0.000302	0.00201	CcSEcCtD
Buprenorphine—Agitation—Temozolomide—melanoma	0.000301	0.002	CcSEcCtD
Buprenorphine—Angioedema—Temozolomide—melanoma	0.000299	0.00199	CcSEcCtD
Buprenorphine—Naloxone—ALB—melanoma	0.000299	0.0887	CrCbGaD
Buprenorphine—Hypotension—Bleomycin—melanoma	0.000296	0.00197	CcSEcCtD
Buprenorphine—Oedema—Dactinomycin—melanoma	0.000296	0.00197	CcSEcCtD
Buprenorphine—Malaise—Temozolomide—melanoma	0.000295	0.00197	CcSEcCtD
Buprenorphine—Vertigo—Temozolomide—melanoma	0.000294	0.00196	CcSEcCtD
Buprenorphine—Convulsion—Carmustine—melanoma	0.000294	0.00195	CcSEcCtD
Buprenorphine—Infection—Dactinomycin—melanoma	0.000294	0.00195	CcSEcCtD
Buprenorphine—Hypertension—Carmustine—melanoma	0.000293	0.00195	CcSEcCtD
Buprenorphine—Palpitations—Temozolomide—melanoma	0.000289	0.00193	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000289	0.00192	CcSEcCtD
Buprenorphine—Chest pain—Carmustine—melanoma	0.000289	0.00192	CcSEcCtD
Buprenorphine—Myalgia—Carmustine—melanoma	0.000289	0.00192	CcSEcCtD
Buprenorphine—Anxiety—Carmustine—melanoma	0.000288	0.00191	CcSEcCtD
Buprenorphine—Cough—Temozolomide—melanoma	0.000286	0.0019	CcSEcCtD
Buprenorphine—Naloxone—ABCB1—melanoma	0.000285	0.0847	CrCbGaD
Buprenorphine—Paraesthesia—Bleomycin—melanoma	0.000285	0.00189	CcSEcCtD
Buprenorphine—Convulsion—Temozolomide—melanoma	0.000284	0.00189	CcSEcCtD
Buprenorphine—Weight decreased—Docetaxel—melanoma	0.000283	0.00188	CcSEcCtD
Buprenorphine—Hypertension—Temozolomide—melanoma	0.000283	0.00188	CcSEcCtD
Buprenorphine—Dyspnoea—Bleomycin—melanoma	0.000282	0.00188	CcSEcCtD
Buprenorphine—Anorexia—Dactinomycin—melanoma	0.000282	0.00187	CcSEcCtD
Buprenorphine—Confusional state—Carmustine—melanoma	0.000279	0.00186	CcSEcCtD
Buprenorphine—Arthralgia—Temozolomide—melanoma	0.000279	0.00186	CcSEcCtD
Buprenorphine—Myalgia—Temozolomide—melanoma	0.000279	0.00186	CcSEcCtD
Buprenorphine—Infestation NOS—Docetaxel—melanoma	0.000279	0.00185	CcSEcCtD
Buprenorphine—Infestation—Docetaxel—melanoma	0.000279	0.00185	CcSEcCtD
Buprenorphine—Anxiety—Temozolomide—melanoma	0.000278	0.00185	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000277	0.00184	CcSEcCtD
Buprenorphine—Oedema—Carmustine—melanoma	0.000277	0.00184	CcSEcCtD
Buprenorphine—Discomfort—Temozolomide—melanoma	0.000275	0.00183	CcSEcCtD
Buprenorphine—Decreased appetite—Bleomycin—melanoma	0.000275	0.00183	CcSEcCtD
Buprenorphine—Infection—Carmustine—melanoma	0.000275	0.00183	CcSEcCtD
Buprenorphine—Dry mouth—Temozolomide—melanoma	0.000273	0.00181	CcSEcCtD
Buprenorphine—Pain—Bleomycin—melanoma	0.000271	0.0018	CcSEcCtD
Buprenorphine—Conjunctivitis—Docetaxel—melanoma	0.000271	0.0018	CcSEcCtD
Buprenorphine—Tachycardia—Carmustine—melanoma	0.00027	0.0018	CcSEcCtD
Buprenorphine—Confusional state—Temozolomide—melanoma	0.000269	0.00179	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000269	0.00179	CcSEcCtD
Buprenorphine—Oedema—Temozolomide—melanoma	0.000267	0.00178	CcSEcCtD
Buprenorphine—Anaphylactic shock—Temozolomide—melanoma	0.000267	0.00178	CcSEcCtD
Buprenorphine—Infection—Temozolomide—melanoma	0.000266	0.00177	CcSEcCtD
Buprenorphine—Anorexia—Carmustine—melanoma	0.000264	0.00175	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Docetaxel—melanoma	0.000264	0.00175	CcSEcCtD
Buprenorphine—Nervous system disorder—Temozolomide—melanoma	0.000262	0.00174	CcSEcCtD
Buprenorphine—Feeling abnormal—Bleomycin—melanoma	0.000261	0.00174	CcSEcCtD
Buprenorphine—Skin disorder—Temozolomide—melanoma	0.00026	0.00173	CcSEcCtD
Buprenorphine—Hypotension—Carmustine—melanoma	0.000258	0.00172	CcSEcCtD
Buprenorphine—Hyperhidrosis—Temozolomide—melanoma	0.000258	0.00172	CcSEcCtD
Buprenorphine—Decreased appetite—Dactinomycin—melanoma	0.000257	0.00171	CcSEcCtD
Buprenorphine—Fatigue—Dactinomycin—melanoma	0.000255	0.0017	CcSEcCtD
Buprenorphine—Anorexia—Temozolomide—melanoma	0.000255	0.0017	CcSEcCtD
Buprenorphine—Pain—Dactinomycin—melanoma	0.000253	0.00168	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Carmustine—melanoma	0.000252	0.00168	CcSEcCtD
Buprenorphine—Urticaria—Bleomycin—melanoma	0.000252	0.00167	CcSEcCtD
Buprenorphine—Rhinitis—Docetaxel—melanoma	0.000251	0.00167	CcSEcCtD
Buprenorphine—Body temperature increased—Bleomycin—melanoma	0.00025	0.00167	CcSEcCtD
Buprenorphine—Insomnia—Carmustine—melanoma	0.00025	0.00166	CcSEcCtD
Buprenorphine—Hypoaesthesia—Docetaxel—melanoma	0.000249	0.00166	CcSEcCtD
Buprenorphine—Paraesthesia—Carmustine—melanoma	0.000248	0.00165	CcSEcCtD
Buprenorphine—Pharyngitis—Docetaxel—melanoma	0.000248	0.00165	CcSEcCtD
Buprenorphine—Urinary tract disorder—Docetaxel—melanoma	0.000247	0.00164	CcSEcCtD
Buprenorphine—Dyspnoea—Carmustine—melanoma	0.000247	0.00164	CcSEcCtD
Buprenorphine—Oedema peripheral—Docetaxel—melanoma	0.000246	0.00164	CcSEcCtD
Buprenorphine—Somnolence—Carmustine—melanoma	0.000246	0.00164	CcSEcCtD
Buprenorphine—Connective tissue disorder—Docetaxel—melanoma	0.000246	0.00164	CcSEcCtD
Buprenorphine—Urethral disorder—Docetaxel—melanoma	0.000245	0.00163	CcSEcCtD
Buprenorphine—Feeling abnormal—Dactinomycin—melanoma	0.000244	0.00162	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000244	0.00162	CcSEcCtD
Buprenorphine—Insomnia—Temozolomide—melanoma	0.000242	0.00161	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Dactinomycin—melanoma	0.000242	0.00161	CcSEcCtD
Buprenorphine—Visual impairment—Docetaxel—melanoma	0.000241	0.0016	CcSEcCtD
Buprenorphine—Decreased appetite—Carmustine—melanoma	0.00024	0.0016	CcSEcCtD
Buprenorphine—Paraesthesia—Temozolomide—melanoma	0.00024	0.0016	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Carmustine—melanoma	0.000239	0.00159	CcSEcCtD
Buprenorphine—Dyspnoea—Temozolomide—melanoma	0.000238	0.00159	CcSEcCtD
Buprenorphine—Somnolence—Temozolomide—melanoma	0.000238	0.00158	CcSEcCtD
Buprenorphine—Pain—Carmustine—melanoma	0.000237	0.00157	CcSEcCtD
Buprenorphine—Constipation—Carmustine—melanoma	0.000237	0.00157	CcSEcCtD
Buprenorphine—Dyspepsia—Temozolomide—melanoma	0.000235	0.00157	CcSEcCtD
Buprenorphine—Eye disorder—Docetaxel—melanoma	0.000234	0.00156	CcSEcCtD
Buprenorphine—Abdominal pain—Dactinomycin—melanoma	0.000234	0.00155	CcSEcCtD
Buprenorphine—Body temperature increased—Dactinomycin—melanoma	0.000234	0.00155	CcSEcCtD
Buprenorphine—Hypersensitivity—Bleomycin—melanoma	0.000233	0.00155	CcSEcCtD
Buprenorphine—Decreased appetite—Temozolomide—melanoma	0.000232	0.00155	CcSEcCtD
Buprenorphine—Flushing—Docetaxel—melanoma	0.000232	0.00154	CcSEcCtD
Buprenorphine—Cardiac disorder—Docetaxel—melanoma	0.000232	0.00154	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Temozolomide—melanoma	0.000231	0.00154	CcSEcCtD
Buprenorphine—Fatigue—Temozolomide—melanoma	0.00023	0.00153	CcSEcCtD
Buprenorphine—Constipation—Temozolomide—melanoma	0.000229	0.00152	CcSEcCtD
Buprenorphine—Pain—Temozolomide—melanoma	0.000229	0.00152	CcSEcCtD
Buprenorphine—Feeling abnormal—Carmustine—melanoma	0.000228	0.00152	CcSEcCtD
Buprenorphine—Asthenia—Bleomycin—melanoma	0.000227	0.00151	CcSEcCtD
Buprenorphine—Angiopathy—Docetaxel—melanoma	0.000227	0.00151	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Carmustine—melanoma	0.000226	0.0015	CcSEcCtD
Buprenorphine—Immune system disorder—Docetaxel—melanoma	0.000226	0.0015	CcSEcCtD
Buprenorphine—Mediastinal disorder—Docetaxel—melanoma	0.000225	0.0015	CcSEcCtD
Buprenorphine—Chills—Docetaxel—melanoma	0.000224	0.00149	CcSEcCtD
Buprenorphine—Pruritus—Bleomycin—melanoma	0.000224	0.00149	CcSEcCtD
Buprenorphine—Feeling abnormal—Temozolomide—melanoma	0.00022	0.00147	CcSEcCtD
Buprenorphine—Mental disorder—Docetaxel—melanoma	0.000219	0.00146	CcSEcCtD
Buprenorphine—Body temperature increased—Carmustine—melanoma	0.000219	0.00145	CcSEcCtD
Buprenorphine—Abdominal pain—Carmustine—melanoma	0.000219	0.00145	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Temozolomide—melanoma	0.000219	0.00145	CcSEcCtD
Buprenorphine—Malnutrition—Docetaxel—melanoma	0.000218	0.00145	CcSEcCtD
Buprenorphine—Erythema—Docetaxel—melanoma	0.000218	0.00145	CcSEcCtD
Buprenorphine—Hypersensitivity—Dactinomycin—melanoma	0.000218	0.00145	CcSEcCtD
Buprenorphine—Dysgeusia—Docetaxel—melanoma	0.000213	0.00142	CcSEcCtD
Buprenorphine—Urticaria—Temozolomide—melanoma	0.000212	0.00141	CcSEcCtD
Buprenorphine—Asthenia—Dactinomycin—melanoma	0.000212	0.00141	CcSEcCtD
Buprenorphine—Abdominal pain—Temozolomide—melanoma	0.000211	0.00141	CcSEcCtD
Buprenorphine—Body temperature increased—Temozolomide—melanoma	0.000211	0.00141	CcSEcCtD
Buprenorphine—Back pain—Docetaxel—melanoma	0.000211	0.0014	CcSEcCtD
Buprenorphine—Muscle spasms—Docetaxel—melanoma	0.000209	0.00139	CcSEcCtD
Buprenorphine—Hypersensitivity—Carmustine—melanoma	0.000204	0.00136	CcSEcCtD
Buprenorphine—Diarrhoea—Dactinomycin—melanoma	0.000202	0.00135	CcSEcCtD
Buprenorphine—Vomiting—Bleomycin—melanoma	0.000201	0.00134	CcSEcCtD
Buprenorphine—Rash—Bleomycin—melanoma	0.0002	0.00133	CcSEcCtD
Buprenorphine—Dermatitis—Bleomycin—melanoma	0.0002	0.00133	CcSEcCtD
Buprenorphine—Asthenia—Carmustine—melanoma	0.000198	0.00132	CcSEcCtD
Buprenorphine—Hypersensitivity—Temozolomide—melanoma	0.000197	0.00131	CcSEcCtD
Buprenorphine—Syncope—Docetaxel—melanoma	0.000195	0.0013	CcSEcCtD
Buprenorphine—Palpitations—Docetaxel—melanoma	0.000192	0.00128	CcSEcCtD
Buprenorphine—Asthenia—Temozolomide—melanoma	0.000192	0.00128	CcSEcCtD
Buprenorphine—Loss of consciousness—Docetaxel—melanoma	0.000191	0.00127	CcSEcCtD
Buprenorphine—Cough—Docetaxel—melanoma	0.00019	0.00126	CcSEcCtD
Buprenorphine—Diarrhoea—Carmustine—melanoma	0.000189	0.00126	CcSEcCtD
Buprenorphine—Pruritus—Temozolomide—melanoma	0.000189	0.00126	CcSEcCtD
Buprenorphine—Convulsion—Docetaxel—melanoma	0.000189	0.00126	CcSEcCtD
Buprenorphine—Nausea—Bleomycin—melanoma	0.000188	0.00125	CcSEcCtD
Buprenorphine—Hypertension—Docetaxel—melanoma	0.000188	0.00125	CcSEcCtD
Buprenorphine—Vomiting—Dactinomycin—melanoma	0.000188	0.00125	CcSEcCtD
Buprenorphine—Rash—Dactinomycin—melanoma	0.000186	0.00124	CcSEcCtD
Buprenorphine—Arthralgia—Docetaxel—melanoma	0.000185	0.00123	CcSEcCtD
Buprenorphine—Chest pain—Docetaxel—melanoma	0.000185	0.00123	CcSEcCtD
Buprenorphine—Myalgia—Docetaxel—melanoma	0.000185	0.00123	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000184	0.00123	CcSEcCtD
Buprenorphine—Dizziness—Carmustine—melanoma	0.000183	0.00122	CcSEcCtD
Buprenorphine—Diarrhoea—Temozolomide—melanoma	0.000183	0.00122	CcSEcCtD
Buprenorphine—Dry mouth—Docetaxel—melanoma	0.000181	0.00121	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—melanoma	0.000179	0.00119	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—melanoma	0.000178	0.00118	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—melanoma	0.000178	0.00118	CcSEcCtD
Buprenorphine—Dizziness—Temozolomide—melanoma	0.000177	0.00118	CcSEcCtD
Buprenorphine—Infection—Docetaxel—melanoma	0.000177	0.00117	CcSEcCtD
Buprenorphine—Vomiting—Carmustine—melanoma	0.000176	0.00117	CcSEcCtD
Buprenorphine—Nausea—Dactinomycin—melanoma	0.000176	0.00117	CcSEcCtD
Buprenorphine—Shock—Docetaxel—melanoma	0.000175	0.00116	CcSEcCtD
Buprenorphine—Rash—Carmustine—melanoma	0.000174	0.00116	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—melanoma	0.000174	0.00116	CcSEcCtD
Buprenorphine—Dermatitis—Carmustine—melanoma	0.000174	0.00116	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—melanoma	0.000173	0.00115	CcSEcCtD
Buprenorphine—Headache—Carmustine—melanoma	0.000173	0.00115	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—melanoma	0.000173	0.00115	CcSEcCtD
Buprenorphine—Vomiting—Temozolomide—melanoma	0.00017	0.00113	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—melanoma	0.000169	0.00113	CcSEcCtD
Buprenorphine—Rash—Temozolomide—melanoma	0.000169	0.00112	CcSEcCtD
Buprenorphine—Dermatitis—Temozolomide—melanoma	0.000168	0.00112	CcSEcCtD
Buprenorphine—Headache—Temozolomide—melanoma	0.000167	0.00111	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—melanoma	0.000166	0.00111	CcSEcCtD
Buprenorphine—Nausea—Carmustine—melanoma	0.000164	0.00109	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000162	0.00108	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—melanoma	0.000161	0.00107	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—melanoma	0.00016	0.00106	CcSEcCtD
Buprenorphine—Nausea—Temozolomide—melanoma	0.000159	0.00106	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—melanoma	0.000158	0.00105	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—melanoma	0.000158	0.00105	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—melanoma	0.000156	0.00104	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—melanoma	0.000155	0.00103	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—melanoma	0.000153	0.00102	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—melanoma	0.000153	0.00102	CcSEcCtD
Buprenorphine—Pain—Docetaxel—melanoma	0.000152	0.00101	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—melanoma	0.000152	0.00101	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—melanoma	0.000146	0.000975	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—melanoma	0.000145	0.000967	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—melanoma	0.000141	0.000935	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—melanoma	0.000141	0.000935	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—melanoma	0.000131	0.000871	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—melanoma	0.000128	0.000849	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—melanoma	0.000126	0.000837	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—melanoma	0.000122	0.000809	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—melanoma	0.000118	0.000782	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—melanoma	0.000113	0.000752	CcSEcCtD
Buprenorphine—Rash—Docetaxel—melanoma	0.000112	0.000746	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—melanoma	0.000112	0.000745	CcSEcCtD
Buprenorphine—Headache—Docetaxel—melanoma	0.000111	0.000741	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—melanoma	0.000106	0.000703	CcSEcCtD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—melanoma	6.61e-06	5.02e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CG—melanoma	6.59e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ERCC2—melanoma	6.58e-06	5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—BRAF—melanoma	6.57e-06	4.99e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CB—melanoma	6.55e-06	4.98e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—melanoma	6.54e-06	4.97e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MDM2—melanoma	6.52e-06	4.95e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD44—melanoma	6.5e-06	4.93e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNAQ—melanoma	6.5e-06	4.93e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—melanoma	6.49e-06	4.93e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—melanoma	6.47e-06	4.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNAQ—melanoma	6.44e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD44—melanoma	6.44e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—melanoma	6.42e-06	4.88e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—melanoma	6.41e-06	4.87e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1—melanoma	6.4e-06	4.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLA2G6—melanoma	6.38e-06	4.85e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CD—melanoma	6.38e-06	4.84e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK1—melanoma	6.37e-06	4.84e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—melanoma	6.37e-06	4.84e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—melanoma	6.36e-06	4.83e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CB—melanoma	6.34e-06	4.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CD—melanoma	6.32e-06	4.8e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.31e-06	4.79e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—melanoma	6.3e-06	4.78e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—melanoma	6.28e-06	4.77e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP17A1—melanoma	6.27e-06	4.76e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1A—melanoma	6.26e-06	4.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.25e-06	4.74e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—melanoma	6.25e-06	4.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ABCB1—melanoma	6.25e-06	4.74e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—melanoma	6.24e-06	4.74e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1B1—melanoma	6.23e-06	4.73e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NFKB1—melanoma	6.22e-06	4.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAP2K1—melanoma	6.19e-06	4.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	6.18e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1B1—melanoma	6.17e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CD—melanoma	6.15e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	6.1e-06	4.63e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—melanoma	6.1e-06	4.63e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—melanoma	6.09e-06	4.63e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	6.09e-06	4.62e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—melanoma	6.05e-06	4.6e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—melanoma	6.02e-06	4.57e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.98e-06	4.54e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—melanoma	5.95e-06	4.52e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNA11—melanoma	5.92e-06	4.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGF2—melanoma	5.89e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—melanoma	5.89e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—melanoma	5.83e-06	4.43e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—melanoma	5.82e-06	4.42e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CD—melanoma	5.8e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—melanoma	5.79e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—FASN—melanoma	5.79e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PRKCA—melanoma	5.75e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—VCAN—melanoma	5.73e-06	4.35e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—melanoma	5.72e-06	4.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ERCC2—melanoma	5.7e-06	4.33e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC5A5—melanoma	5.7e-06	4.33e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—melanoma	5.68e-06	4.31e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—melanoma	5.66e-06	4.3e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—melanoma	5.64e-06	4.28e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—melanoma	5.62e-06	4.27e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—melanoma	5.59e-06	4.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—melanoma	5.58e-06	4.23e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—melanoma	5.57e-06	4.23e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CB—melanoma	5.56e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—melanoma	5.53e-06	4.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CB—melanoma	5.51e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—melanoma	5.51e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—melanoma	5.51e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MDM2—melanoma	5.51e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNAQ—melanoma	5.5e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD44—melanoma	5.5e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—melanoma	5.49e-06	4.17e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—melanoma	5.48e-06	4.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—melanoma	5.46e-06	4.15e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKB1—melanoma	5.45e-06	4.14e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.45e-06	4.14e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—melanoma	5.43e-06	4.12e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	5.39e-06	4.09e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—melanoma	5.36e-06	4.07e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—melanoma	5.34e-06	4.06e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	5.34e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—melanoma	5.34e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1B1—melanoma	5.28e-06	4.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—melanoma	5.2e-06	3.95e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—melanoma	5.19e-06	3.94e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—melanoma	5.15e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PRKCA—melanoma	5.13e-06	3.9e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—melanoma	5.13e-06	3.89e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—melanoma	5.12e-06	3.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—melanoma	5.09e-06	3.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—melanoma	5.08e-06	3.86e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK1—melanoma	5.08e-06	3.86e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—melanoma	5.08e-06	3.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—melanoma	5.05e-06	3.84e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—melanoma	5.05e-06	3.84e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—melanoma	5.03e-06	3.82e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—melanoma	5.02e-06	3.81e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PRKCA—melanoma	5.01e-06	3.8e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—melanoma	5.01e-06	3.8e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—melanoma	4.97e-06	3.78e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—melanoma	4.97e-06	3.77e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—melanoma	4.95e-06	3.76e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—melanoma	4.93e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—melanoma	4.92e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—melanoma	4.9e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—melanoma	4.9e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—melanoma	4.89e-06	3.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP17A1—melanoma	4.84e-06	3.67e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—melanoma	4.8e-06	3.65e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—melanoma	4.8e-06	3.64e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—melanoma	4.8e-06	3.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—melanoma	4.76e-06	3.62e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—melanoma	4.75e-06	3.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.72e-06	3.59e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PRKCA—melanoma	4.72e-06	3.58e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—melanoma	4.68e-06	3.55e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—melanoma	4.68e-06	3.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PRKCA—melanoma	4.68e-06	3.55e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—melanoma	4.66e-06	3.54e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.66e-06	3.54e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—melanoma	4.64e-06	3.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—melanoma	4.64e-06	3.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—melanoma	4.63e-06	3.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKB1—melanoma	4.61e-06	3.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—melanoma	4.57e-06	3.47e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNA11—melanoma	4.57e-06	3.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—melanoma	4.55e-06	3.46e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—melanoma	4.52e-06	3.43e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—melanoma	4.51e-06	3.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—melanoma	4.5e-06	3.42e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—FASN—melanoma	4.47e-06	3.39e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK1—melanoma	4.45e-06	3.38e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—melanoma	4.45e-06	3.38e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—melanoma	4.41e-06	3.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A5—melanoma	4.4e-06	3.34e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—melanoma	4.37e-06	3.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—melanoma	4.35e-06	3.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—melanoma	4.35e-06	3.3e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—melanoma	4.26e-06	3.24e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD44—melanoma	4.25e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNAQ—melanoma	4.25e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.22e-06	3.2e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—melanoma	4.21e-06	3.19e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—melanoma	4.18e-06	3.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—melanoma	4.14e-06	3.14e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—melanoma	4.13e-06	3.14e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—melanoma	4.13e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—melanoma	4.08e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1B1—melanoma	4.07e-06	3.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—melanoma	4.02e-06	3.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PRKCA—melanoma	4e-06	3.04e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—melanoma	4e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—melanoma	3.98e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—melanoma	3.97e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—melanoma	3.96e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—melanoma	3.96e-06	3e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—melanoma	3.95e-06	3e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—melanoma	3.92e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—melanoma	3.91e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—melanoma	3.9e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—melanoma	3.88e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—melanoma	3.87e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—melanoma	3.85e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.84e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—melanoma	3.79e-06	2.87e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK1—melanoma	3.76e-06	2.86e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—melanoma	3.76e-06	2.86e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—melanoma	3.74e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—melanoma	3.7e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—melanoma	3.67e-06	2.78e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—melanoma	3.6e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—melanoma	3.58e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—melanoma	3.57e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—melanoma	3.56e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—melanoma	3.54e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—melanoma	3.53e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—melanoma	3.49e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—melanoma	3.45e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—melanoma	3.45e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—melanoma	3.44e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—melanoma	3.42e-06	2.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—melanoma	3.42e-06	2.6e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—melanoma	3.4e-06	2.58e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—melanoma	3.39e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—melanoma	3.36e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—melanoma	3.35e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.29e-06	2.49e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—melanoma	3.27e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—melanoma	3.26e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—melanoma	3.25e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—melanoma	3.22e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—melanoma	3.21e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—melanoma	3.18e-06	2.41e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—melanoma	3.16e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—melanoma	3.16e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—melanoma	3.13e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PRKCA—melanoma	3.09e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—melanoma	3.08e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—melanoma	3.08e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—melanoma	3.06e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—melanoma	3.05e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—melanoma	3.02e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—melanoma	3.02e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—melanoma	3.01e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—melanoma	2.98e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—melanoma	2.98e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—melanoma	2.89e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—melanoma	2.83e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—melanoma	2.81e-06	2.13e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—melanoma	2.81e-06	2.13e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—melanoma	2.78e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—melanoma	2.77e-06	2.1e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—melanoma	2.75e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—melanoma	2.74e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—melanoma	2.72e-06	2.06e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—melanoma	2.67e-06	2.03e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—melanoma	2.66e-06	2.02e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—melanoma	2.6e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—melanoma	2.52e-06	1.91e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—melanoma	2.45e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—melanoma	2.43e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—melanoma	2.43e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—melanoma	2.42e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—melanoma	2.4e-06	1.82e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—melanoma	2.38e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—melanoma	2.33e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—melanoma	2.12e-06	1.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—melanoma	2.1e-06	1.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—melanoma	2.1e-06	1.59e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—melanoma	2.07e-06	1.57e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—melanoma	1.98e-06	1.51e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—melanoma	1.88e-06	1.43e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—melanoma	1.85e-06	1.41e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—melanoma	1.84e-06	1.39e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—melanoma	1.83e-06	1.39e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—melanoma	1.73e-06	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—melanoma	1.72e-06	1.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—melanoma	1.71e-06	1.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—melanoma	1.6e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—melanoma	1.53e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—melanoma	1.5e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—melanoma	1.46e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—melanoma	1.41e-06	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—melanoma	1.4e-06	1.06e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—melanoma	1.2e-06	9.07e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—melanoma	1.13e-06	8.57e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—melanoma	9.22e-07	7e-06	CbGpPWpGaD
